Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Nanoparticles Are a Cancer Fight Gamechanger

Dr. Loralyn Mears is the Director of Scientific Communications for Global Cancer Technology. “How are nanoparticles changing the fight against cancer? Most of us know someone who has, unfortunately, been diagnosed with cancer, and we see the typical treatments, right? Typically, [it involves] chemotherapy, radiation, and surgery to remove the tumors and then blast them with…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Dr. Loralyn Mears is the Director of Scientific Communications for Global Cancer Technology.

“How are nanoparticles changing the fight against cancer? Most of us know someone who has, unfortunately, been diagnosed with cancer, and we see the typical treatments, right?

Typically, [it involves] chemotherapy, radiation, and surgery to remove the tumors and then blast them with high intense levels of radiation that give you a sunburn for years.

I’m a cancer survivor. The other way is, of course, chemotherapy, highly toxic drugs, which have to be at that level of effectiveness so that they can kill the cancers, which are notoriously difficult, because they like to replicate uncontrollably. That’s what cancer cells do, but they also hurt the rest of the body.

What if you could change things around where you had a nanoparticle that could carry the payload specifically to the destination? Right to the tumor. Remember those clap on, clap off lights from the 70s?

Well, anyway, people really liked them before, but, with that kind of remote controlled precision, you could activate the particles and say, OK, we can see we’ve tracked you. You’ve all made it to the destination, which is the tumor. And now, with a remote activation, boom, the nanoparticles are triggered. They’re activated by a very low blast of X-ray dose, and they release their payload directly into the tumor cell.

Now, isn’t that something worth talking about? And this is what Global Cancer Technology is currently working on — to make it so that these nanoparticles are used both diagnostically and for treatments, particularly in those hard-to-reach cancers like brain cancer.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS launches dedicated health technology office as AI and interoperability pressure mounts on hospital IT teams

CMS launches dedicated health technology office as AI and interoperability pressure mounts on hospital IT teams

The Centers for Medicare & Medicaid Services (CMS) have established a new Office of Health Technology and Products. This office aims to integrate AI, promote interoperability, and advance digital health strategies, thereby increasing demands on hospital IT teams.

  • 01CMS has launched an Office of Health Technology and Products to focus on AI, interoperability, and digital health strategy.
  • 02The new CMS office will increase demands and expectations on hospital IT teams.
  • 03Improving interoperability and integrating AI in healthcare is a crucial priority for CMS.

Jul 18, 2026

Medical device supply chains face persistent pressure as federal glove push falls short

Medical device supply chains face persistent pressure as federal glove push falls short

The medical device supply chain is under sustained pressure due to various factors including domestic glove manufacturing failures and product shortages in hospitals. Additionally, there is intense competition in the $1.5 billion heart valve market. These challenges are causing shifts in medtech supply signals.

  • 01The medical device supply chain is experiencing continued stress due to manufacturing failures and shortages.
  • 02Domestic glove manufacturing efforts have not met expectations, contributing to supply chain issues.
  • 03The heart valve market faces increased competition valued at $1.5 billion.

Jul 18, 2026

From Chaos to Control: Dr. Mo Canellas on AI, Emergency Medicine & Why Most “AI Companies” Fake It

From Chaos to Control: Dr. Mo Canellas on AI, Emergency Medicine & Why Most “AI Companies” Fake It

Dr. Maureen 'Mo' Canellas discusses the implementation of AI in emergency medicine and critiques the authenticity of many companies claiming to be AI-focused. She highlights her roles at UMass Memorial Medical Center and collaborations with institutions like MIT. Dr. Canellas also contributes to discussions around health care operations and benchmarking.

  • 01Dr. Mo Canellas is a significant figure in emergency medicine, focusing on machine learning and healthcare operations.
  • 02Many companies claiming to focus on AI in healthcare do not genuinely implement such technology.
  • 03Dr. Canellas collaborates with MIT and the Emergency Department Benchmarking Alliance for health care research and advancement.

Jul 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512